References

1
Ikkala E. Haemophilia. A study of its laboratory, clinical, genetic and social aspects based on known haemophiliacs in Finland. Scalpel (Brux) 1960; 12: 1.
2
Patek AJ, Taylor FHL. Hemophilia. II. Some properties of a substance obtained from normal human plasma effective in accelerating the coagulation of hemophilic blood. J Clin Invest 1937; 16: 113–24. doi:10.1172/JCI100829.
3
Nilsson IM, Blombäck M, Jorpes E, Blombäck B, Johansson S-A. v. Willebrand’s Disease and its Correction with Human Plasma Fraction 1-0. Acta Med Scand 1957; 159: 179–88. doi:10.1111/j.0954-6820.1957.tb00123.x.
4
Ahlberg Å, Nilsson IM, Bauer GC. Use of Antihemophilic Factor (Plasma Fraction I-0) during Correction of Knee-Joint Deformities in Hemophilia A: REPORT OF THREE CASES INCLUDING ONE OSTEOTOMY. J Bone Joint Surg Am 1965; 47: 323–32.
5
Mannucci PM. Back to the future: A recent history of haemophilia treatment. Haemophilia 2008; 14: 10–8. doi:10.1111/j.1365-2516.2008.01708.x.
6
Nilsson I, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25–32. doi:10.1111/j.1365-2796.1992.tb00546.x.
7
Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–44. doi:10.1056/NEJMoa067659.
8
Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: A beneficial effect on orthopaedic outcome and quality of life. Eur J Haematol 2012; 88: 329–35. doi:10.1111/j.1600-0609.2012.01750.x.
9
Skinner MW, Nugent D, Wilton P, O’Mahony B, Dolan G, O’Hara J, et al. Achieving the unimaginable: Health equity in haemophilia. Haemophilia 2020; 26: 17–24. doi:doi.org/10.1111/hae.13862.
10
Hermans C, Moerloose P de, Dolan G. Clinical management of older persons with haemophilia. Crit Rev Oncol Hematol 2014; 89: 197–206. doi:10.1016/j.critrevonc.2013.07.005.
11
Colvin B, Astermark J, Fischer K, Gringeri A, Lassila R, Schramm W, et al. European principles of haemophilia care. Haemophilia 2008; 14: 361–74. doi:10.1111/j.1365-2516.2007.01625.x.
12
Soucie JM, Nuss R, Evatt B, Abdelhak A, Cowan L, Hill H, et al. Mortality among males with hemophilia: Relations with source of medical care. Blood 2000; 96: 437–42. doi:10.1182/blood.V96.2.437.
13
Lassila R, Armstrong E. Current challenges of pharmacovigilance in bleeding disorders: Converting the burden to benefit. Haemophilia 2010; 16: 231–7. doi:10.1111/j.1365-2516.2009.02102.x.
14
European Haemophilia Network. EUHANET 2019.
15
Kitchen S, Adcock DM, Dauer R, Kristoffersen A-H, Lippi G, Mackie I, et al. International Council for Standardisation in Haematology (ICSH) recommendations for collection of blood samples for coagulation testing. Int J Lab Hematol 2021; 43: 571–80. doi:10.1111/ijlh.13584.
16
Kitchen S, Adcock DM, Dauer R, Kristoffersen A-H, Lippi G, Mackie I, et al. International Council for Standardization in Haematology (ICSH) recommendations for processing of blood samples for coagulation testing. Int J Lab Hematol 2021; 43: 1272–83. doi:10.1111/ijlh.13702.
17
Kitchen S, Paula CF de, Lima MS de, Gouider E, Kaczmarek R, Tagny C, et al. WFH Guidelines for the Management of Hemophilia, Chapter 3: Laboratory Diagnosis and Monitoring, 3rd edition. Haemophilia 2020; 26: 1–158. doi:10.1111/hae.14046#hae14046-sec-0073-title.
18
Peyvandi F, Oldenburg J, Friedman K. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost 2016; 14: 248–61. doi:10.1111/jth.13215.
19
Pavlova A, Delev D, Pezeshkpoor B, Müller J, Oldenburg J. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays. Thromb Haemost 2014; 112: 851–61. doi:10.1160/TH13-08-0690.
20
Bowyer A, Duncan E, Antovic J. Role of chromogenic assays in haemophilia A and B diagnosis. Haemophilia 2018; 24: 578–83. doi:10.1111/hae.13520.
21
Kihlberg K, Strandberg K, Rosen S, Ljung R, Astermark J. Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B. Haemophilia 2017; 23: 620–7. doi:10.1111/hae.13219.
22
Potgieter JJ, Damgaard M, Hillarp A. One-stage vs. chromogenic assays in haemophilia A. Eur J Haematol 2015; 94: 38–44. doi:10.1111/ejh.12500.
23
Miller C. Laboratory testing for factor VIII and IX inhibitors in haemophilia: a review. Haemophilia 2018; 24: 186–97. doi:10.1111/hae.13424.
24
Kitchen S, Tiefenbacher S, Gosselin R. Factor activity assays for monitoring extended half-life FVIII and factor IX replacement therapies. Semin Thromb Hemost 2017; 43: 331–7. doi:10.1055/s-0037-1598058.
25
Adcock D, Strandberg K, Shima M, Marlar R. Advantages, disadvantages and optimization of one-stage and chromogenic factor activity assays in haemophilia A and B. Int J Lab Hematol 2018; 40: 621–9. doi:10.1111/ijlh.12877.
26
Müller J, Goldmann G, Marquardt N, Pötzsch B, Oldenburg J. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management. Hämostaseologie 2020; 40: S15–20. doi:10.1055/a-1282-225.
27
Augustsson C, Norström E, Lind V, Martin M, Astermark J, Strandberg K. Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays. Haemophilia 2021; 27: 494–500. doi:10.1111/hae.14317.
28
Bowyer AE, Lowe AE, Tiefenbacher S. Laboratory issues in gene therapy and emicizumab. Haemophilia 2021; 27: 142–7. doi:10.1111/hae.13976.
29
Gomez K, Laffan M, Keeney S, Sutherland M, Curry N, Lunt P. Recommendations for the clinical interpretation of genetic variants and presentation of results to patients with inherited bleeding disorders. A UK Haemophilia Centre Doctors’ Organisation Good Practice Paper. Haemophilia 2019; 25: 116–26. doi:10.1111/hae.13637.
30
Lakich D, Kazazian HH, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe haemophilia A. Nat Genet 1993; 5: 236. doi:10.1038/ng1193-236.
31
European EAHAD Coagulation Factor Variant Databases n.d. https://dbs.eahad.org.
32
American CDC Hemophilia Mutation Project databases CHAMP/CHBM n.d. https://www.cdc.gov/ncbddd/hemophilia/champs.html.
33
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in medicine 2015; 17: 405–23. doi:10.1038/gim.2015.30.
34
Manderstedt E, Nilsson R, Ljung R, Lind-Halldén C, Astermark J, Halldén C. Detection of mosaics in hemophilia A by deep Ion Torrent sequencing and droplet digital PCR. Research and practice in thrombosis and haemostasis 2020; 4: 1121–30. doi:10.1002/rth2.12425.
35
Manderstedt E, Lind-Halldén C, Ljung R, Astermark J, Halldén C. Detection of F8 int22h inversions using digital droplet PCR and mile-post assays. Journal of Thrombosis and Haemostasis 2020; 18: 1039–49. doi:10.1111/jth.14760.
36
Leuer M, Oldenburg J, Lavergne J-M, Ludwig M, Fregin A, Eigel A, et al. Somatic mosaicism in hemophilia A: a fairly common event. Am J Hum Genet 2001; 69: 75–87. doi:10.1086/321285.
37
Green P, Saad S, Lewis C, Giannelli F. Mutation rates in humans. I. Overall and sex-specific rates obtained from a population study of hemophilia B. Am J Hum Genet 1999; 65: 1572–9. doi:10.1086/302651.
38
Lavery S. Preimplantation genetic diagnosis of haemophilia. Br J Haematol 2009; 144: 303–7. doi:10.1111/j.1365-2141.2008.07391.x.
39
Laurie A, Hill A, Harraway J, Fellowes A, Phillipson G, Benny P, et al. Preimplantation genetic diagnosis for hemophilia A using indirect linkage analysis and direct genotyping approaches. J Thromb Haemost 2010; 8: 783–9. doi:10.1111/j.1538-7836.2010.03768.x.
40
Blanchette V, Key N, Ljung L, Manco-Johnson M, Van Den Berg H, Srivastava A, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1935–9. doi:10.1111/jth.12672.
41
Fischer K, Carlsson KS, Petrini P, Holmström M, Ljung R, Berg HM van den, et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 2013; 122: 1129–36. doi:10.1182/blood-2012-12-470898.
42
Steen Carlsson K, Höjgård S, Glomstein A, Lethagen S, Schulman S, Tengborn L, et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia 2003; 9: 555–66. doi:10.1046/j.1365-2516.2003.00817.x.
43
Berntorp E, Astermark J, Baghaei F, Bergqvist D, Holmström M, Ljungberg B, et al. Treatment of haemophilia A and B and von Willebrand’s disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment. Haemophilia 2012; 18: 158–65. doi:10.1111/j.1365-2516.2011.02723.x.
44
Berntorp E, Andersson NG. Prophylaxis for hemophilia in the era of extended half-life factor VIII/factor IX products. Semin Thromb Hemost 2016; 42: 518–25. doi:10.1055/s-0036-1571315.
45
Feldman BM, Funk SM, Bergstrom B-M, Zourikian N, Hilliard P, Net J van der, et al. Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken) 2011; 63: 223–30. doi:10.1002/acr.20353.
46
Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res 1980: 153–9.
47
Chan M, Leckie A, Xavier F, Uleryk E, Tadros S, Blanchette V, et al. A systematic review of MR imaging as a tool for evaluating haemophilic arthropathy in children. Haemophilia 2013; 19: e324–34. doi:10.1111/hae.12248.
48
Lundin B, Manco-Johnson M, Ignas D, Moineddin R, Blanchette V, Dunn A, et al. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia 2012; 18: 962–70. doi:10.1111/j.1365-2516.2012.02883.x.
49
Nijdam A, Foppen W, Van der Schouw Y, Mauser-Bunschoten E, Schutgens R, Fischer K. Long-term effects of joint bleeding before starting prophylaxis in severe haemophilia. Haemophilia 2016; 22: 852–8. doi:10.1111/hae.12959.
50
Andersson NG, Auerswald G, Barnes C, Carcao M, Dunn AL, Fijnvandraat K, et al. Intracranial haemorrhage in children and adolescents with severe haemophilia A or B–the impact of prophylactic treatment. Br J Haematol 2017; 179: 298–307. doi:10.1111/bjh.14844.
51
Shima M, Nogami K, Nagami S, Yoshida S, Yoneyama K, Ishiguro A, et al. A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia 2019; 25: 979–87. doi:10.1111/hae.13848.
52
Barg AA, Livnat T, Budnik I, Avishai E, Brutman-Barazani T, Tamarin I, et al. Emicizumab treatment and monitoring in a paediatric cohort: Real-world data. Br J Haematol 2020; 191: 282–90. doi:10.1111/bjh.16964.
53
Hassan E, Jonathan L, Jayashree M. Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors. Haemophilia 2021; 27: e698–703. doi:10.1111/hae.14432.
54
Teo HKW, Wong WH, Lam JCM. Recurrent intracranial bleed in a child receiving prophylaxis with emicizumab. Haemophilia 2021; 27: e415–8. doi:10.1111/hae.14274.
55
Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016; 374: 2054–64. doi:10.1056/NEJMoa1516437.
56
Konigs C, Ozelo M, Dunn A, Kulkarni R, Nolan B, Brown S, et al. Final Results of PUPs A-LONG Study: Evaluating Safety and Efficacy of rFVIIIFc in Previously Untreated Patients with Haemophilia A (abstr.). Res Pract Thromb Haemost 2020; 4.
57
Nolan B, Klukowska A, Shapiro A, Rauch A, Recht M, Ragni M, et al. Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B. Blood Adv 2021; 5: 2732–9. doi:10.1182/bloodadvances.2020004085.
58
Vepsäläinen K, Lassila R, Arola M, Lähteenmäki P, Möttönen M, Mäkipernaa A, et al. Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland. Haemophilia 2015; 21: 747–53. doi:10.1111/hae.12665.
59
Khair K, Ranta S, Thomas A, Lindvall K, Group PS. The impact of clinical practice on the outcome of central venous access devices in children with haemophilia. Haemophilia 2017; 23: e276–81. doi:10.1111/hae.13241.
60
Maclean P, Richards M, Williams M, Collins P, Liesner R, Keeling D, et al. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia 2011; 17: 282–7. doi:10.1111/j.1365-2516.2010.02422.x.
61
Gouw SC, Bom JG van der, Van Den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648–54. doi:10.1182/blood-2006-11-056291.
62
Gouw SC, Berg HM van den, Fischer K, Auerswald G, Carcao M, Chalmers E, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121: 4046–55. doi:10.1182/blood-2012-09-457036.
63
Vepsäläinen K, Lassila R, Arola M, Huttunen P, Koskinen S, Ljung R, et al. Inhibitor development in previously untreated patients with severe haemophilia A: a nationwide multicentre study in Finland. Haemophilia 2016; 22: 721–9. doi:10.1111/hae.12974.
64
Nijdam A, Kurnik K, Liesner R, Ljung R, Nolan B, Petrini P, et al. How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. Haemophilia 2015; 21: 444–50. doi:10.1111/hae.12613.
65
Petrini P, Seuser A. Haemophilia care in adolescents–compliance and lifestyle issues. Haemophilia 2009; 15: 15–9. doi:10.1111/j.1365-2516.2008.01948.x.
66
Young G. From boy to man: recommendations for the transition process in haemophilia. Haemophilia 2012; 18: 27–32. doi:10.1111/j.1365-2516.2012.02893.x.
67
Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy–global progress towards optimal care. Haemophilia 2006; 12: 75–81. doi:10.1111/j.1365-2516.2006.01189.x.
68
Lindvall K, Colstrup L, Wollter I-M, Klemenz G, Loogna K, Grönhaug S, et al. Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia. Haemophilia 2006; 12: 47–51. doi:10.1111/j.1365-2516.2006.01192.x.
69
Astermark J, Dolan G, Hilberg T, Jiménez-Yuste V, Laffan M, Lassila R, et al. Managing haemophilia for life: 4th Haemophilia global summit. Haemophilia 2014; 20: 1–20. doi:10.1111/hae.12468.
70
Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546–51. doi:10.1182/blood-2006-04-017988.
71
Young G, Shafer F, Rojas P, Seremetis S. Single 270 \(\mu\)g kg- 1-dose rFVIIa vs. standard 90 \(\mu\)g kg- 1-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14: 287–94. doi:10.1111/j.1365-2516.2007.01601.x.
72
Schneiderman J, Rubin E, Nugent D, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244–8. doi:10.1111/j.1365-2516.2007.01451.x.
73
Ingerslev J, Sørensen B. Parallel use of by-passing agents in haemophilia with inhibitors: a critical review. Br J Haematol 2011; 155: 256–62. doi:10.1111/j.1365-2141.2011.08854.x.
74
Teitel J, Berntorp E, Collins P, d’Oiron R, Ewenstein B, Gomperts E, et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256–63. doi:10.1111/j.1365-2516.2007.01449.x.
75
Konkle B, Ebbesen L, Erhardtsen E, Bianco R, Lissitchkov T, Rusen L, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904–13. doi:10.1111/j.1538-7836.2007.02663.x.
76
Leissinger C, Gringeri A, Antmen B, Berntorp E, Biasoli C, Carpenter S, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684–92. doi:10.1056/NEJMoa1104435.
77
Antunes S, Tangada S, Stasyshyn O, Mamonov V, Phillips J, Guzman-Becerra N, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 20: 65–72. doi:10.1111/hae.12246.
78
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377: 809–18. doi:10.1056/NEJMoa1703068.
79
Nogami K, Shima M. New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood 2019; 133: 399–406. doi:10.1182/blood-2018-07-820712.
80
Rocino A, Cortesi P, Scalone L, Mantovani L, Crea R, Gringeri A, et al. Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study). Haemophilia 2016; 22: 96–102. doi:10.1111/hae.12780.
81
Hay CR, DiMichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335–44. doi:10.1182/blood-2011-08-369132.
82
Rocino A, Santagostino E, Mancuso ME, Mannucci PM. Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica 2006; 91: 558–61.
83
Velzen AS van, Peters M, Bom JG van der, Fijnvandraat K. Effect of von W illebrand factor on inhibitor eradication in patients with severe haemophilia A: a systematic review. Br J Haematol 2014; 166: 485–95. doi:10.1111/bjh.12942.
84
Berntorp E, Astermark J, Carlborg E. Immune tolerance induction and the treatment of hemophilia. Malmö protocol update. Haematologica 2000; 85: 48–50.
85
Beutel K, Hauch H, Rischewski J, Kordes U, Schneppenheim J, Schneppenheim R. ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor. Hämostaseologie 2009; 29: 155–7.
86
Darby SC, Keeling DM, Spooner RJ, Wan Kan S, Giangrande PL, Collins PW, et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99. J Thromb Haemost 2004; 2: 1047–54. doi:10.1046/j.1538-7836.2004.00710.x.
87
Eckhardt CL, Van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013; 122: 1954–62. doi:10.1182/blood-2013-02-483263.
88
Kempton CL, Allen G, Hord J, Kruse-Jarres R, Pruthi RK, Walsh C, et al. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol 2012; 87: 933–6. doi:10.1002/ajh.23269.
89
Kulkarni R. Comprehensive care of the patient with haemophilia and inhibitors undergoing surgery: practical aspects. Haemophilia 2013; 19: 2–10. doi:10.1111/j.1365-2516.2012.02922.x.
90
Ingerslev J, Hvid I. Surgery in hemophilia. The general view: patient selection, timing, and preoperative assessment. Semin Hematol 2006; 43: S23–6. doi:10.1053/j.seminhematol.2005.11.024.
91
Holme P, Tjønnfjord G, Batorova A. Continuous infusion of coagulation factor concentrates during intensive treatment. Haemophilia 2018; 24: 24–32. doi:10.1111/hae.13331.
92
Srivastava A, Brewer A, Mauser-Bunschoten E, Key N, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1–47. doi:10.1111/j.1365-2516.2012.02909.x.
93
Ljung RC, Knobe K. How to manage invasive procedures in children with haemophilia. Br J Haematol 2012; 157: 519–28. doi:10.1111/j.1365-2141.2012.09089.x.
94
Hermans C, Altisent C, Batorova A, Chambost H, De Moerloose P, Karafoulidou A, et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009; 15: 639–58. doi:10.1111/j.1365-2516.2008.01950.x.
95
Coppola A, Castaman G, Santoro RC, Mancuso ME, Franchini M, Marino R, et al. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia 2020; 26: 937–45. doi:10.1111/hae.14172.
96
Tjønnfjord G, Brinch L, Gedde-Dahl III T, Brosstad F. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10: 174–8. doi:10.1046/j.1365-2516.2003.00857.x.
97
Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116: 5734–7. doi:10.1182/blood-2010-06-291906.
98
Holmström M, Tran H, Holme P. Combined treatment with APCC (FEIBA) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A–a two-centre experience. Haemophilia 2012; 18: 544–9. doi:10.1111/j.1365-2516.2012.02748.x.
99
Rangarajan S, Austin S, Goddard N, Négrier C, Rodriguez-Merchan E, Stephensen D, et al. Consensus recommendations for the use of FEIBA in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery. Haemophilia 2013; 19: 294–303. doi:10.1111/hae.12028.
100
Holme P, Tran H, Paus A, Tjonnfjord G. Surgery in haemophilia patients with inhibitors to FVIII/FIX: the Norwegian single centre study: O-WE-028. J Thromb Haemost 2011; 9 (Suppl 2): 512.
101
Teitel J, Carcao M, Lillicrap D, Mulder K, Rivard G, St-Louis J, et al. Orthopaedic surgery in haemophilia patients with inhibitors: a practical guide to haemostatic, surgical and rehabilitative care. Haemophilia 2009; 15: 227–39. doi:10.1111/j.1365-2516.2008.01840.x.
102
Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998; 80: 773–8.
103
Pruthi RK, Mathew P, Valentino LA, Sumner MJ, Seremetis S, Hoots KW, et al. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Thromb Haemost 2007; 98: 726–32.
104
Valentino L, Cooper D, Goldstein B. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia 2011; 17: 579–89. doi:10.1111/j.1365-2516.2010.02460.x.
105
Makris M, Hay C, Gringeri A, D’oiron R. How I treat inhibitors in haemophilia. Haemophilia 2012; 18: 48–53. doi:10.1111/j.1365-2516.2012.02829.x.
106
Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 2012; 18: 1570–4. doi:10.1038/nm.2942.
107
Collins PW, Liesner R, Makris M, Talks K, Chowdary P, Chalmers E, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia 2018; 24: 344–7. doi:10.1111/hae.13495.
108
Jiménez-Yuste V, Rodríguez-Merchán EC, Matsushita T, Holme PA. Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery. Haemophilia 2021; 27: 519–30. doi:10.1111/hae.14322.
109
Lewandowska M, Randall N, Bakeer N, Maahs J, Sagar J, Greist A, et al. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US. Haemophilia 2021; 27: 90–9. doi:10.1111/hae.14212.
110
Krumb E, Fijnvandraat K, Makris M, Peyvandi F, Ryan A, Athanasopoulos A, et al. Adoption of emicizumab (Hemlibra) for hemophilia A in Europe: Data from the 2020 European Association for Haemophilia and Allied Disorders survey. Haemophilia 2021; 27: 736–43. doi:10.1111/hae.14372.
111
Mahlangu J, Andreeva T, Macfarlane D, Walsh C, Key N. Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. Haemophilia 2017; 23: 33–41. doi:10.1111/hae.13108.
112
Croteau SE, Abajas YL, Wolberg AS, Nielsen BI, Marx GR, Baird CW, et al. Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor. Haemophilia 2017; 23: e93–8. doi:10.1111/hae.13157.
113
Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol 2010; 148: 522–33. doi:10.1111/j.1365-2141.2009.08005.x.
114
Khleif AA, Rodriguez N, Brown D, Escobar MA. Multiple comorbid conditions among middle-aged and elderly hemophilia patients: prevalence estimates and implications for future care. J Aging Res 2011; 2011. doi:10.4061/2011/985703.
115
Marchesini E, Oliovecchio E, Coppola A, Santagostino E, Radossi P, Castaman G, et al. Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population. Haemophilia 2018; 24: e6. doi:10.1111/hae.13379.
116
Miesbach W, Reitter-Pfoertner S-E, Klamroth R, Langer F, Wolf H-H, Tiede A, et al. Co-morbidities and bleeding in elderly patients with haemophilia—A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH). Haemophilia 2017; 23: 721–7. doi:10.1111/hae.13296.
117
Harrison C, Saccullo G, Makris M. Haemophilia of the third age. Haemophilia 2017; 24: 5–16. doi:10.1111/hae.13257.
118
Hollingdrake O, Mutch A, Zeissink B, Lawler S, David M, Fitzgerald L. Haemophilia and age-related comorbidities: do men with haemophilia consult a general practitioner for men’s preventative health checks? Haemophilia 2016; 22: e335–7. doi:10.1111/hae.12968.
119
Boccalandro E, Mancuso M, Riva S, Pisaniello D, Ronchetti F, Santagostino E, et al. Ageing successfully with haemophilia: a multidisciplinary programme. Haemophilia 2018; 24: 57–62. doi:10.1111/hae.13308.
120
Stephensen D, Rodriguez-Merchan E. Orthopaedic co-morbidities in the elderly haemophilia population: a review. Haemophilia 2013; 19: 166–73. doi:10.1111/hae.12006.
121
Mannucci PM, Schutgens RE, Santagostino E, Mauser-Bunschoten EP. How I treat age-related morbidities in elderly persons with hemophilia. Blood 2009; 114: 5256–63. doi:10.1182/blood-2009-07-215665.
122
Konkle BA. The aging patient with hemophilia. Am J Hematol 2012; 87: S27–32. doi:10.1002/ajh.23161.
123
Gerstner G, Damiano M, Tom A, Worman C, Schultz W, Recht M, et al. Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia 2009; 15: 559–65. doi:10.1111/j.1365-2516.2008.01963.x.
124
Konkle B, Kessler C, Aledort L, Andersen J, Fogarty P, Kouides P, et al. Emerging clinical concerns in the ageing haemophilia patient. Haemophilia 2009; 15: 1197–209. doi:10.1111/j.1365-2516.2009.02066.x.
125
Rosendaal F, Briet E, Stibbe J, Herpen G van, Leuven JG, Hofman A, et al. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990; 75: 525–30. doi:10.1111/j.1365-2141.1990.tb07793.x.
126
Coppola A, Santoro C, Franchini M, Mannucci C, Mogavero S, Molinari AC, et al. Emerging issues on comprehensive hemophilia care: Preventing, identifying, and monitoring age-related comorbidities. Semin Thromb Hemost 2013; 39: 794–802. doi:10.1055/s-0033-1354424.
127
Dolan G. The challenge of an ageing haemophilic population. Haemophilia 2010; 16: 11–6. doi:10.1111/j.1365-2516.2010.02287.x.
128
Coppola A, Tagliaferri A, Franchini M. The management of cardiovascular diseases in patients with hemophilia. Semin Thromb Hemost 2010; 31: 091–102. doi:10.1055/s-0030-1248728.
129
Schutgens R, Tuinenburg A, Roosendaal G, Guyomi SH, Mauser-Bunschoten E. Treatment of ischaemic heart disease in haemophilia patients: an institutional guideline. Haemophilia 2009; 15: 952–8. doi:10.1111/j.1365-2516.2009.02020.x.
130
Martin K, Key NS. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood 2016; 128: 178–84. doi:10.1182/blood-2015-12-635094.
131
Bar-Chama N, Snyder S, Aledort L. Sexual evaluation and treatment of ageing males with haemophilia. Haemophilia 2011; 17: 875–83. doi:10.1111/j.1365-2516.2011.02507.x.
132
Holme PA, Tait RC, Combescure C, Berntorp E, Tagliaferri A, Staritz P, et al. Renal status and hematuria in older patients with hemophilia 2015.
133
Holme PA, Combescure C, Tait RC, Berntorp E, Rauchensteiner S, Moerloose P de, et al. Hypertension, haematuria and renal functioning in haemophilia–a cross-sectional study in Europe. Haemophilia 2016; 22: 248–55. doi:10.1111/hae.12847.
134
Franchini M, Lippi G, Montagnana M, Targher G, Zaffanello M, Salvagno GL, et al. Hemophilia and cancer: a new challenge for hemophilia centers. Cancer Treat Rev 2009; 35: 374–7. doi:10.1016/j.ctrv.2009.01.001.
135
Astermark J, Makris M, Mauser-Bunschoten E, Nemes L, D’oiron R, Oldenburg J, et al. Malignant disease in the haemophilic population: moving towards a management consensus? Haemophilia 2012; 18: 664–71. doi:10.1111/j.1365-2516.2012.02846.x.
136
Fogarty P, Kouides P. How we manage prostate biopsy and prostate cancer therapy in men with haemophilia. Haemophilia 2012; 18: e88–90. doi:10.1111/j.1365-2516.2012.02787.x.
137
Moerloose P de, Fischer K, Lambert T, Windyga J, Bátorová A, LAVIGNE-LISSALDE G, et al. Recommendations for assessment, monitoring and follow-up of patients with haemophilia. Haemophilia 2012; 18: 319–25. doi:10.1111/j.1365-2516.2011.02671.x.
138
Witkop M, Lambing A, Divine G, Kachalsky E, Rushlow D, Dinnen J. A national study of pain in the bleeding disorders community: a description of haemophilia pain. Haemophilia 2012; 18: e115–9. doi:10.1111/j.1365-2516.2011.02709.x.
139
Riley RR, Witkop M, Hellman E, Akins S. Assessment and management of pain in haemophilia patients. Haemophilia 2011; 17: 839–45. doi:10.1111/j.1365-2516.2011.02567.x.
140
Humphries T, Kessler C. The challenge of pain evaluation in haemophilia: can pain evaluation and quantification be improved by using pain instruments from other clinical situations? Haemophilia 2013; 19: 181–7. doi:10.1111/hae.12023.
141
Holstein K, Klamroth R, Richards M, Carvalho M, PÉREZ-GARRIDO R, Gringeri A, et al. Pain management in patients with haemophilia: a European survey. Haemophilia 2012; 18: 743–52. doi:10.1111/j.1365-2516.2012.02808.x.
142
Polston G, Wallace M. Analgesic agents in rheumatic disease. Elsevier; 2013.
143
Cheng OT, Souzdalnitski D, Vrooman B, Cheng J. Evidence-based knee injections for the management of arthritis. Pain Med 2012; 13: 740–53. doi:10.1111/j.1526-4637.2012.01394.x.
144
Shupak R, Teitel J, Garvey M, Freedman J. Intraarticular methylprednisolone therapy in hemophilic arthropathy. Am J Hematol 1988; 27: 26–9. doi:10.1002/ajh.2830270107.
145
Fernández-Palazzi F, Caviglia HA, Salazar JR, López J, Aoun R. Intraarticular dexamethasone in advanced chronic synovitis in hemophilia. Clin Orthop Relat Res 1997: 25–9.
146
Lobet S, Timmer M, Königs C, Stephensen D, McLaughlin P, Duport G, et al. The role of physiotherapy in the new treatment landscape for haemophilia. J Clin Med 2021; 10: 2822. doi:10.3390/jcm10132822.
147
Wells A, Stephensen D. The role of the physiotherapist in the management of people with haemophilia: Defining the new normal. Br J Hosp Med 2020; 81: 1–8. doi:10.12968/hmed.2020.0016.
148
Timmer MA, Blokzijl J, Schutgens RE, Veenhof C, Pisters MF. Coordinating physiotherapy care for persons with haemophilia. Haemophilia 2021; 27: 1051–61. doi:10.1111/hae.14404.
149
Flannery T, Bladen M, Hopper D, Jones S, McLaughlin P, Penn A, et al. Physiotherapy after COVID-19—“Zoom or room”. Haemophilia 2020. doi:10.1111/hae.14166.
150
Boccalandro EA, Dallari G, Mannucci PM. Telemedicine and telerehabilitation: Current and forthcoming applications in haemophilia. Blood Transfus 2019; 17: 385. doi:10.2450/2019.0218-18.
151
Wagner B, Seuser A, Krüger S, Herzig ML, Hilberg T, Ay C, et al. Establishing an online physical exercise program for people with hemophilia. Wien Klin Wochenschr 2019; 131: 558–66. doi:10.1007/s00508-019-01548-1.
152
O’Donovan M, Buckley C, Benson J, Roche S, McGowan M, Parkinson L, et al. Telehealth for delivery of haemophilia comprehensive care during the COVID-19 pandemic. Haemophilia 2020; 26: 984–90. doi:10.1111/hae.14156.
153
Mulder K, McCabe E, Strike K, Nilson J. Developing clinical practice guidelines for physiotherapists working with people with inherited bleeding disorders. Haemophilia 2021; 27: 674–82. doi:10.1111/hae.14327.
154
Engelbert RH, Plantinga M, Van der Net J, Van Genderen FR, Van den Berg MH, Helders PJ, et al. Aerobic capacity in children with hemophilia. J Pediatr 2008; 152: 833–8. doi:10.1016/j.jpeds.2007.12.016.
155
Tlacuilo-Parra A, Morales-Zambrano R, Tostado-Rabago N, Esparza-Flores MA, Lopez-Guido B, Orozco-Alcala J. Inactivity is a risk factor for low bone mineral density among haemophilic children. Br J Haematol 2008; 140: 562–7. doi:10.1111/j.1365-2141.2007.06972.x.
156
Al-Sharif FA-G, Al-Jiffri OH, El-Kader SMA, Ashmawy EM. Impact of mild versus moderate intensity aerobic walking exercise training on markers of bone metabolism and hand grip strength in moderate hemophilic A patients. Afr Health Sci 2014; 14: 11–6. doi:10.4314/ahs.v14i1.3.
157
Gomis M, Querol F, Gallach J, González L, Aznar J. Exercise and sport in the treatment of haemophilic patients: a systematic review. Haemophilia 2009; 15: 43–54. doi:10.1111/j.1365-2516.2008.01867.x.
158
Heijnen L. The role of rehabilitation and sports in haemophilia patients with inhibitors. Haemophilia 2008; 14: 45–51. doi:10.1111/j.1365-2516.2008.01889.x.
159
Runkel B, Von Mackensen S, Hilberg T. RCT–subjective physical performance and quality of life after a 6-month programmed sports therapy (PST) in patients with haemophilia. Haemophilia 2017; 23: 144–51. doi:10.1111/hae.13079.
160
Negrier C, Seuser A, Forsyth A, Lobet S, Llinas A, Rosas M, et al. The benefits of exercise for patients with haemophilia and recommendations for safe and effective physical activity. Haemophilia 2013; 19: 487–98. doi:10.1111/hae.12118.
161
Runkel B, Czepa D, Hilberg T. RCT of a 6-month programmed sports therapy (PST) in patients with haemophilia – Improvement of physical fitness. Haemophilia 2016; 22: 765–71. doi:10.1111/hae.12957.
162
Kennedy M, O’Gorman P, Monaghan A, Lavin M, O’Mahony B, O’Connell NM, et al. A systematic review of physical activity in people with haemophilia and its relationship with bleeding phenotype and treatment regimen. Haemophilia 2021; 27: 544–62. doi:10.1111/hae.14282.
163
Beeton K, De Kleijn P, Hilliard P, Funk S, Zourikian N, BERGSTROM B-M, et al. Recent developments in clinimetric instruments. Haemophilia 2006; 12: 102–7. doi:10.1111/j.1365-2516.2006.01265.x.
164
Di Minno M, Pasta G, Airaldi S, Zaottini F, Storino A, Cimino E, et al. Ultrasound for early detection of joint disease in patients with hemophilic arthropathy. J Clin Med 2017; 6: 77. doi:10.3390/jcm6080077.
165
Martinoli C, Alberighi ODC, Di Minno G, Graziano E, Molinari AC, Pasta G, et al. Development and definition of a simplified scanning procedure and scoring method for Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US). Thromb Haemost 2013; 109: 1170–9. doi:10.1160/TH12-11-0874.
166
Stephensen D, Classey S, Harbidge H, Patel V, Taylor S, Wells A. Physiotherapist inter-rater reliability of the Haemophilia Early Arthropathy Detection with Ultrasound protocol. Haemophilia 2018; 24: 471–6. doi:10.1111/hae.13440.
167
Måseide RJ, Berntorp E, Astermark J, Hansen J, Olsson A, Bruzelius M, et al. Haemophilia early arthropathy detection with ultrasound and haemophilia joint health score in the moderate haemophilia (MoHem) study. Haemophilia 2021; 27: e253–9. doi:10.1111/hae.14245.
168
Hilliard P, Funk S, Zourikian N, BERGSTROM B-M, Bradley C, McLimont M, et al. Hemophilia joint health score reliability study. Haemophilia 2006; 12: 518–25. doi:10.1111/j.1365-2516.2006.01312.x.
169
Fischer K, De Kleijn P. Using the Haemophilia Joint Health Score for assessment of teenagers and young adults: exploring reliability and validity. Haemophilia 2013; 19: 944–50. doi:10.1111/hae.12197.
170
Callahan LF, Brooks RH, Summey JA, Pincus T. Quantitative pain assessment for routine care of rheumatoid arthritis patients, using a pain scale based on activities of daily living and a visual analog pain scale. Arthritis Rheum 1987; 30: 630–6. doi:10.1002/art.1780300605.
171
Van Genderen F, Westers P, Heijnen L, De Kleijn P, Van den Berg H, Helders P, et al. Measuring patients’ perceptions on their functional abilities: validation of the Haemophilia Activities List. Haemophilia 2006; 12: 36–46. doi:10.1111/j.1365-2516.2006.01186.x.
172
Poonnoose P, Manigandan C, Thomas R, Shyamkumar N, Kavitha M, Bhattacharji S, et al. Functional Independence Score in Haemophilia: a new performance-based instrument to measure disability. Haemophilia 2005; 11: 598–602. doi:10.1111/j.1365-2516.2005.01142.x.
173
De la Corte-Rodriguez H, Rodriguez-Merchan EC. The Health Assessment Questionnaire Disability Index (HAQ-DI) as a valid alternative for measuring the functional capacity of people with haemophilia. Thromb Res 2017; 153: 51–6. doi:10.1016/j.thromres.2017.03.016.
174
Gurcay E, Eksioglu E, Ezer U, Cakir B, Cakci A. A prospective series of musculoskeletal system rehabilitation of arthropathic joints in young male hemophilic patients. Rheumatol Int 2008; 28: 541–5. doi:10.1007/s00296-007-0474-7.
175
Hanley J, McKernan A, Creagh M, Classey S, McLaughlin P, Goddard N, et al. Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) guideline. Haemophilia 2017; 23: 511–20. doi:10.1111/hae.13201.
176
Guodemar-Pérez J, Ruiz-López M, Rodríguez-López E, García-Fernández P, Hervás-Pérez JP. Physiotherapy Treatments in Musculoskeletal Pathologies Associated with Haemophilia. Hämostaseologie 2018; 38: 141–9. doi:10.5482/HAMO-16-11-0044.
177
Neelapala YR, Attal R, Tandale S. Aquatic exercise for persons with haemophilia: A review of literature. Complement Ther Clin Pract 2019; 34: 195–200. doi:10.1016/j.ctcp.2018.12.004.
178
Young G, Tachdjian R, Baumann K, Panopoulos G. Comprehensive management of chronic pain in haemophilia. Haemophilia 2014; 20: e113–20. doi:10.1111/hae.12349.
179
McLaughlin P, Hurley M, Chowdary P, Khair K, Stephensen D. Physiotherapy interventions for pain management in haemophilia: A systematic review. Haemophilia 2020; 26: 667–84. doi:10.1111/hae.14030.
180
Strike K, Mulder K, Michael R. Exercise for haemophilia. Cochrane Database Syst Rev 2016. doi:10.1002/14651858.CD011180.pub2.
181
Stephensen D, Bladen M, McLaughlin P. Recent advances in musculoskeletal physiotherapy for haemophilia. Ther Adv Hematol 2018; 9: 227–37. doi:10.1177/2040620718784834.
182
Wagner B, Krüger S, Hilberg T, Ay C, Hasenoehrl T, Huber DF-X, et al. The effect of resistance exercise on strength and safety outcome for people with haemophilia: A systematic review. Haemophilia 2020; 26: 200–15. doi:10.1111/hae.13938.
183
De Kleijn P, Blamey G, Zourikian N, Dalzell R, Lobet S. Physiotherapy following elective orthopaedic procedures. Haemophilia 2006; 12: 108–12. doi:10.1111/j.1365-2516.2006.01266.x.
184
Heijnen L, Buzzard BB. The role of physical therapy and rehabilitation in the management of hemophilia in developing countries. Semin Thromb Hemost 2005; 31: 513–7. doi:10.1055/s-2005-922222.
185
Galen KP van, d’Oiron R, James P, Abdul-Kadir R, Kouides PA, Kulkarni R, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH. J Thromb Haemost 2021; 19: 1883–7. doi:10.1111/jth.15397.
186
Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH, Amstel HKP van, Bom JG van der, Diemen-Homan JE van, et al. Bleeding in carriers of hemophilia. Blood 2006; 108: 52–6. doi:10.1182/blood-2005-09-3879.
187
Dunn N, Miller R, Griffioen A, Lee C. Carrier testing in haemophilia A and B: adult carriers’ and their partners’ experiences and their views on the testing of young females. Haemophilia 2008; 14: 584–92. doi:10.1111/j.1365-2516.2007.01649.x.
188
Lee C, Chi C, Pavord S, Bolton-Maggs P, Pollard D, Hinchcliffe-Wood A, et al. The obstetric and gynaecological management of women with inherited bleeding disorders–review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization. Haemophilia 2006; 12: 301–36. doi:10.1111/j.1365-2516.2006.01314.x.
189
Devaney SA, Palomaki GE, Scott JA, Bianchi DW. Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. JAMA 2011; 306: 627–36. doi:10.1001/jama.2011.1114.
190
Elejalde BR, De Elejalde M, Heitman T. Visualization of the fetal genitalia by ultrasonography: a review of the literature and analysis of its accuracy and ethical implications. J Ultrasound Med 1985; 4: 633–9. doi:10.7863/jum.1985.4.12.633.
191
Mujezinovic F, Alfirevic Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet Gynecol 2007; 110: 687–94. doi:10.1097/01.AOG.0000278820.54029.e3.
192
Chi C, Lee C, Shiltagh N, Khan A, Pollard D, Kadir R. Pregnancy in carriers of haemophilia. Haemophilia 2008; 14: 56–64. doi:10.1111/j.1365-2516.2007.01561.x.
193
Sentilhes L, Lasocki S, Ducloy-Bouthors A, Deruelle P, Dreyfus M, Perrotin F, et al. Tranexamic acid for the prevention and treatment of postpartum haemorrhage. Br J Anaesth 2015; 114: 576–87. doi:10.1093/bja/aeu448.
194
Chi C, Lee CA, England A, Hingorani J, Paintsil J, Kadir RA. Obstetric analgesia and anaesthesia in women with inherited bleeding disorders. Thromb Haemost 2009; 101: 1104–11. doi:10.1160/TH08-10-0694.
195
Andersson NG, Chalmers EA, Kenet G, Ljung R, Mäkipernaa A, Chambost H. Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds. haematologica 2019; 104: 2100. doi:10.3324/haematol.2018.209619.
196
Chalmers E, Williams M, Brennand J, Liesner R, Collins P, Richards M, et al. Guideline on the management of haemophilia in the fetus and neonate. Br J Haematol 2011; 154: 208–15. doi:10.1111/j.1365-2141.2010.08545.x.
197
Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW, et al. WFH guidelines for the management of hemophilia. Haemophilia 2020; 26: 1–158. doi:10.1111/hae.14046.
198
Pollard D, Harrison C, Dodgson S, Holland M, Khair K. The UK haemophilia specialist nurse: Competencies fit for practice in the 21st century. Haemophilia 2020; 26: 622–30. doi:10.1111/hae.14002.
199
Myrin Westesson L, Wallengren C, Baghaei F, Sparud-Lundin C. Reaching Independence Through Forced Learning: Learning Processes and Illness Management in Parents of Children Affected by Hemophilia. Qual Health Res 2018; 28: 2142–54. doi:10.1177/1049732318789631.
200
Committee EN, Harrington C, Bedford M, Andritschke K, Barrie A, Elfvinge P, et al. A european curriculum for nurses working in haemophilia. Haemophilia 2016; 22: 103–9. doi:10.1111/hae.12785.
201
Schrijvers L, Beijlevelt-Van der Zande M, Peters M, Lock J, Cnossen M, Schuurmans M, et al. Achieving self-management of prophylactic treatment in adolescents: The case of haemophilia. Patient Educ Couns 2016; 99: 1179–83. doi:10.1016/j.pec.2016.01.016.
202
DeKoven M, Karkare S, Kelley L, Cooper D, Pham H, Powers J, et al. Understanding the experience of caring for children with haemophilia: cross-sectional study of caregivers in the United States. Haemophilia 2014; 20: 541–9. doi:10.1111/hae.12379.
203
DeKoven M, Karkare S, Lee W, Kelley L, Cooper D, Pham H, et al. Impact of haemophilia with inhibitors on caregiver burden in the United States. Haemophilia 2014; 20: 822–30. doi:10.1111/hae.12501.
204
Schrijvers L, Beijlevelt-Van Der Zande M, Peters M, Schuurmans M, Fischer K. Learning intravenous infusion in haemophilia: experience from the Netherlands. Haemophilia 2012; 18: 516–20. doi:10.1111/j.1365-2516.2012.02752.x.
205
Petrini P. Identifying and overcoming barriers to prophylaxis in the management of haemophilia. Haemophilia 2007; 13: 16–22. doi:10.1111/j.1365-2516.2007.01501.x.
206
Lindvall K, Mackensen S von, Elmståhl S, Khair K, Stain AM, Ljung R, et al. Increased burden on caregivers of having a child with haemophilia complicated by inhibitors. Pediatr Blood Cancer 2014; 61: 706–11. doi:10.1002/pbc.24856.
207
Galen K van, Lavin M, Skouw-Rasmussen N, Fischer K, Noone D, Pollard D, et al. European principles of care for women and girls with inherited bleeding disorders. Haemophilia 2021; 27: 837–47. doi:10.1111/hae.14379.
208
Aradom E, Gomez K. The patient gene therapy journey: findings from qualitative interviews with trial participants at one UK Haemophilia centre. J Haem Pract 2021; 8: 32–44. doi:10.17225/jhp00174.
209
Zanon E, Martinelli F, Bacci C, Zerbinati P, Girolami A. Proposal of a standard approach to dental extraction in haemophilia patients. A case-control study with good results. Haemophilia 2000; 6: 533–6. doi:10.1046/j.1365-2516.2000.00423.x.
210
Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lorenz C, et al. Dental procedures in adult patients with hereditary bleeding disorders: 10 years experience in three Italian Hemophilia Centers. Haemophilia 2005; 11: 504–9. doi:10.1111/j.1365-2516.2005.01132.x.
211
Kalsi H, Nanayakkara L, Pasi K, Bowles L, Hart D. Access to primary dental care for patients with inherited bleeding disorders. Haemophilia 2012; 18: 510–5. doi:10.1111/j.1365-2516.2011.02716.x.
212
Lee A, Boyle C, Savidge G, Fiske J. Effectiveness in controlling haemorrhage after dental scaling in people with haemophilia by using tranexamic acid mouthwash. Br Dent J 2005; 198: 33–8. doi:10.1038/sj.bdj.4811955.